Registration, quality assurance and the shape of a medicines contract
A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programs -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.
Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.
The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and program funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.
This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.
Who buys pharmaceuticals in Slovenia?
GlobalGov holds 287 pharmaceuticals records from 66 distinct buying organizations in Slovenia. The most frequent publishers are Univerzitetni Klinični Center Ljubljana (7 records); Lekarniška zbornica Slovenije (6 records); Ministrstvo Za Obrambo (6 records); Splošna bolnišnica Brežice (6 records); UKC Ljubljana (6 records); Univerza V Ljubljani, Biotehniška Fakulteta (6 records). Between them the 6 largest account for 13% of everything published, so buying here is spread across many separate authorities.
| Buying organization | Records | Share |
|---|---|---|
| Univerzitetni Klinični Center Ljubljana | 7 | 2.4% |
| Lekarniška zbornica Slovenije | 6 | 2.1% |
| Ministrstvo Za Obrambo | 6 | 2.1% |
| Splošna bolnišnica Brežice | 6 | 2.1% |
| UKC Ljubljana | 6 | 2.1% |
| Univerza V Ljubljani, Biotehniška Fakulteta | 6 | 2.1% |
What are pharmaceuticals contracts worth in Slovenia?
48 of the 287 records publish a contract value. The median is $687,450 and the largest single published value is $90.8M. By size, 2 under $100k, 27 between $100k and $1M, 13 between $1M and $10M, 6 above $10M. The remaining 239 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.
| Contract size | Records | Share of priced |
|---|---|---|
| under $100k | 2 | 4.2% |
| between $100k and $1M | 27 | 56% |
| between $1M and $10M | 13 | 27% |
| above $10M | 6 | 12% |
How long do bidders get to respond to pharmaceuticals tenders in Slovenia?
Across the 74 Slovenia pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 21 days. A quarter of them allowed 14 days or fewer and a quarter stayed open for more than 31. Short turnarounds are the exception rather than the rule here: only 14 (19%) closed within a fortnight of being published.
How often are pharmaceuticals tenders published in Slovenia?
Slovenia publishes about 8 notices a month in this category, 102 in the last twelve months. That is 538% more than the 16 published in the twelve months before that. Over the last three years there were 129, spread across 60 separate months of activity since 3 September 2007. October is historically the busiest month. The most recent was published 16 November 2026.
How does Slovenia compare with other pharmaceuticals markets?
Among the 45 countries where GlobalGov holds a comparable pharmaceuticals market, Slovenia ranks 27th by number of records. The largest is Poland (9,417 records against 287 here). Within Slovenia itself, pharmaceuticals is the 13th largest of the 39 procurement categories tracked here.
Where do the Slovenia pharmaceuticals records on this page come from?
These 287 records are collected from 2 official sources: TED (271), the Slovenia national tender archive (16). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-11-22.
Open Pharmaceuticals tenders in Slovenia
Showing 3 of the 3 notices open in this category today. Openness uses the same definition as the Slovenia market page: active, not marked awarded, cancelled, closed or expired, and either closing in the future or published within the last 90 days with no stated closing date.
Slovenia – Pharmaceutical products – MEDICINES H, ZZ, Rp and BRp 2025‑2026
Slovenia – Pharmaceutical products – Pharmaceutical substances, dressings, medical and other consumable materials
Other procurement categories in Slovenia
Pharmaceuticals procurement in other markets
Never Miss a Slovenia Government Contract
Finding Slovenia tenders usually means a local portal, a local registration and someone who reads the language. Get an alert you can read when a new pharmaceuticals opportunity is published there.
Start Free Trial